drugset
drugset / Trial / NCT04705077

A Study to Assess the Pharmacokinetics and Food Effect of SR419 in Healthy Subjects

NCT04705077 ↗

Phase 1 Completed 24 enrolled SIMR (Australia) Biotech Pty Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This will be an open-label, single-site, Phase I study to evaluate the PK, safety, and tolerability of SR419 in healthy volunteers.

Timeline

Start
2021-02-02
Primary completion
2021-03-12
Completion
2021-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject SR419 Unknown 30 mg —

Indications

No indication recorded.